Significance of genetic polymorphism of CYP2D6 in the pathogenesis of systemic sclerosis.
BACKGROUND
Systemic sclerosis (SSc) belongs to the group of systemic diseases of the connective tissue, which are characterized by a chronic autoimmune inflammatory process. The studies on etiopathogenesis of autoimmune diseases focus on the impact the genetically conditioned impairment of xenobiotic metabolism may exert. The genetically polymorphic CYP2D6 is one of the most important phase I drug metabolizing enzymes. The knowledge of oxidation polymorphism in the course of SSc may be helpful in choosing more efficient and safer therapy, particularly in the case of a disease involving various organs and treated with drugs belonging to diverse therapeutic groups. The aim of the study was to evaluate the CYP2D6 polymorphism in the SSc patients and to investigate a possible correlation with disease susceptibility.


METHODS
The study was carried out in 77 patients with SSc and 129 healthy volunteers. The CYP2D6 genotypes were analyzed by polymerase chain reaction fragment length polymorphism (PCR-RFLP) method.


RESULTS
Risk of SSc development for particular genotype carriers expressed by the odds ratio (OR) was statistically significantly higher for subjects with CYP2D6*1/CYP2D6*4 (OR = 3.2; p = 0.001). A statistically significant correlation between the CYP2D6*4 allele prevalence and the risk for developing SSc was found (OR = 1.6; p = 0.029).


CONCLUSIONS
The obtained results may suggest the influence of CYP2D6*4 gene mutated alleles on increased incidence of systemic sclerosis.
Department of Pharmacogenetics, Medical University of Lodz, Muszyńskiego 1, PL 90-151 Łódź, Poland. malgorzata.baranska@umed.lodz.pl
Małgorzata
M
Barańska
Bożena
B
Dziankowska-Bartkowiak
Elżbieta
E
Waszczykowska
Mariola
M
Rychlik-Sych
Jadwiga
J
Skrętkowicz
D000293:Adolescent; D000328:Adult; D000368:Aged; D000483:Alleles; D016022:Case-Control Studies; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D003627:Data Interpretation, Statistical; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D015994:Incidence; D008297:Male; D050216:Metabolic Detoxication, Phase I; D008875:Middle Aged; D009154:Mutation; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D012595:Scleroderma, Systemic / Q000201:enzymology / Q000453:epidemiology / Q000235:genetics*; D015262:Xenobiotics / Q000493:pharmacokinetics; D055815:Young Adult
D015262:Xenobiotics; D019389:Cytochrome P-450 CYP2D6